Does Acamprosate Increase Blood Pressure?
No, acamprosate does not increase blood pressure; in fact, it may cause transient diastolic hypotension rather than hypertension.
Evidence from FDA Drug Label
The FDA-approved prescribing information for acamprosate lists hypertension among the nervous system adverse events, but this is categorized as "frequent" alongside other neurological symptoms like somnolence, tremor, and vasodilatation 1. However, this listing does not establish causation and appears in the context of a comprehensive adverse event profile from clinical trials where many events may be coincidental or related to alcohol withdrawal/relapse rather than the drug itself.
Importantly, the FDA label does not highlight hypertension as a warning, precaution, or serious adverse event requiring monitoring 11. The primary safety concerns emphasized are:
- Suicidality and depression
- Renal impairment
- Sulfite sensitivity
- Acute kidney failure (postmarketing)
Blood pressure elevation is notably absent from these priority safety concerns.
Clinical Research Evidence
The most direct evidence suggests acamprosate may actually lower blood pressure:
A 1992 randomized, double-blind trial in 24 cirrhotic patients found that acute administration of acamprosate (666 mg) caused transient diastolic hypotension without significant systolic blood pressure changes 2. This is the opposite effect from hypertension.
A recent 2025 phase 2 safety trial in patients with alcohol-associated liver disease found no significant adverse events related to blood pressure over 12 weeks of acamprosate treatment 3. This study specifically monitored safety parameters and found the drug well-tolerated.
Context from Guidelines
Multiple systematic reviews and network meta-analyses examining acamprosate for alcohol use disorder 44 do not identify hypertension as a notable adverse effect. These comprehensive analyses, which pooled data from thousands of patients, focused on dropout rates and serious adverse events—hypertension was not flagged as a concern.
Clinical Bottom Line
Monitor patients for hypotension rather than hypertension when initiating acamprosate, particularly:
- During the first few hours after dosing (when transient diastolic drops may occur)
- In patients with baseline low blood pressure
- In those taking concurrent antihypertensive medications
- In patients with cirrhosis or significant liver disease
The "hypertension" listing in the FDA adverse event table likely reflects background rates in alcohol-dependent populations (who have high cardiovascular risk) rather than a drug effect. The only blood pressure change with evidence of causation is transient diastolic hypotension, not hypertension.